1197958-53-4
1197958-53-4 structure
- Name: ALK-IN-12
- Chemical Name: AP26113
- CAS Number: 1197958-53-4
- Molecular Formula:
- Molecular Weight:
- Catalog: Signaling Pathways Protein Tyrosine Kinase/RTK ALK
- Create Date: 2018-06-28 17:43:02
- Modify Date: 2024-01-17 14:25:34
-
ALK-IN-12 is a potent and orally active ALK inhibitor with an IC50 of 0.18 nM. ALK-IN-12 also inhibits IGF1R and InsR (IC50=20.3 and 90.6 nM). Antitumor activities[1].
| Name | AP26113 |
|---|
| Description | ALK-IN-12 is a potent and orally active ALK inhibitor with an IC50 of 0.18 nM. ALK-IN-12 also inhibits IGF1R and InsR (IC50=20.3 and 90.6 nM). Antitumor activities[1]. |
|---|---|
| Related Catalog | |
| In Vitro | ALK-IN-12 (compound 11e) effectively inhibits viability of the Karpas-299 ALCL cell line with an IC50 of 28.3 nM[1]. |
| In Vivo | ALK-IN-12 (10-50 mg/kg; orally; once daily for 13 consecutive days) shows dose-dependent antitumor activity[1]. ALK-IN-12 (3 mg/kg; i.v.; 6-8 week old female CD rats ) treatment shows AUC0-∞, CL, t1/2 and Vss are 3039 ng•h/mL, 0.91 h•kg, 6.6 hours and 6.12 L/kg, respectively[1]. ALK-IN-12 (10 mg/kg; p.o.; 6-8 week old female CD rats) treatment shows Cmax, AUC0-∞, tmax, t1/2 and F are 3254 ng/mL, 4056 ng•h/mL, 6.0 hours, 12.5 hours and 39%, respectively[1]. Animal Model: Eight- to 10-week old female SCID/beige mice (Karpas-299 xenograft mouse model expressing the NPM-ALK fusion)[1] Dosage: 10-50 mg/kg Administration: Orally; once daily for 13 consecutive days Result: Dose-dependent antitumor activity. Led to tumor stasis (50 mg/kg dose). |
| References |
| No Any Chemical & Physical Properties |